Regulatory and ClinicalApr 15, 2025 · 3:58pm ET
MIRAMIRA Pharmaceuticals, Inc. Common Stock
MIRA Pharmaceuticals' Ketamir-2 Demonstrates Efficacy in Animal Study for Diabetes-Associated Nerve Damage
Results indicate potential therapeutic benefits for diabetic neuropathy.
Regulatory and ClinicalApr 15, 2025 · 3:58pm ET
MIRAMIRA Pharmaceuticals, Inc. Common Stock+58.0%
MIRA Pharmaceuticals' Ketamir-2 Demonstrates Efficacy in Animal Study for Diabetes-Associated Nerve Damage